Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations

@inproceedings{Khtreiber2018LongtermRI,
  title={Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations},
  author={Willem M. K{\"u}htreiber and Lisa Tran and Taesoo Kim and Michael P Dybala and Brian T Nguyen and Sara S. Plager and Daniel Huang and Sophie E. Janes and Audrey Defusco and Danielle Baum and Hui Jun Zheng and Denise L Faustman},
  booktitle={npj Vaccines},
  year={2018}
}
Mycobacterium are among the oldest co-evolutionary partners of humans. The attenuated Mycobacterium bovis Bacillus Calmette Guérin (BCG) strain has been administered globally for 100 years as a vaccine against tuberculosis. BCG also shows promise as treatment for numerous inflammatory and autoimmune diseases. Here, we report on a randomized 8-year long prospective examination of type 1 diabetic subjects with long-term disease who received two doses of the BCG vaccine. After year 3, BCG lowered… CONTINUE READING
BETA

From This Paper

Figures and tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes

  • Faustman, L D.
  • PLoS One 7,
  • 2012
Highly Influential
12 Excerpts

Similar Papers

Loading similar papers…